Organigram did not buy Germany’s Sanity Group just to add revenue. It bought the rest of the margin. That is the blunt economics Finn Hänsel, Organigram’s chief strategy officer and president rest of world, laid out in an interview with IgniteIt, and it is the clearest articulation yet of how the smart international cannabis plays actually work.
The numbers first, with the caveat attached. Hänsel says Sanity generated €8 million in 2023, €19 million in 2024, and €60 million in 2025, and projects roughly €120 million for 2026, possibly more. Those are management’s figures, not independently verified guidance. But the trajectory is the point. Eight to a hundred twenty in three years.
How does owning the whole chain change the math?
Before the deal, Organigram sold cannabis to Sanity and kept the cultivation margin. Sanity then sold into German pharmacies and kept the distribution margin. Two companies, two margins. Now it is one company, and Hänsel’s framing is direct: “we capture the whole margin from cultivation to the pharmacy.”
Sanity did about C$40 million in its most recent quarter with roughly 100 employees and margins he puts between 30 and 40 percent, though he did not specify which margin measure, so do not read that as EBITDA. The acquisition also buys control over procurement, inventory planning, and product development, plus the ability to plan production months ahead based on actual German demand. “We know exactly the end to end cost of the product,” he said. In a market where prices are under pressure, that visibility is the whole game.
Why is Germany still the growth engine?
Germany’s 2024 medical cannabis liberalization, removing cannabis from the narcotics framework, cut the administrative friction on prescriptions and opened the door for digital healthcare services. It is the same regulatory shift that keeps making Germany an increasingly interesting medical market for real patient outcomes. Hänsel credits the market shift alongside Sanity’s own investments in distribution, supply chain, digital platforms, and brands.
He estimates the German medical market at roughly €2 billion today and expects it to double again over the next two to three years. His assessment, not an independent forecast. But even discounted, the direction is clear, which is why Germany stays Organigram’s largest international growth bet. It is the same compounding dynamic driving cannabis up the ranks of Canada’s cash crops.
Where does the expansion go next?
The United Kingdom is next, with a target of 10 to 15 percent market share within three years, which would make it the company’s second largest market outside Canada. Poland follows, though product approvals there can take up to two years, so Hänsel expects a meaningful presence by late 2027. Australia, Brazil, and smaller European markets are on the evaluation list, with a warning that big populations do not mean big opportunities where regulations or purchasing power limit the market.
That is expansion with a filter, the kind shareholder value actually requires instead of the map painting exercises that burned the first wave of Canadian LPs.
What protects the margin as competition rises?
Brands. “The only thing that helps you from price compression is people who believe in your brand,” Hänsel said. Sanity runs three: Avai in premium, Zoic in value, Viamede for the clinical patient. Concentrated, differentiated, and built to hold pricing power when products become interchangeable.
The open question is integration. Organigram has more than 1,000 employees. Sanity had fewer than 100. Keeping the small company’s speed inside the big company’s scale is where these deals live or die, and Hänsel has said as much about retaining Sanity’s best talent.
Revenue is the headline. The margin is the business. Watch whether the second follows the first.
FAQs
- What did Organigram buy?
Germany’s Sanity Group. The deal pairs Organigram’s cultivation scale with Sanity’s distribution into German pharmacies. - What are the revenue figures?
€8M in 2023, €19M in 2024, €60M in 2025, and roughly €120M projected for 2026. Those are management’s figures, not independently verified guidance. - What is the margin play?
One company now captures the full chain from cultivation to the pharmacy counter, with margins cited between 30 and 40 percent (the measure was not specified). - Which markets are next?
The UK, with a 10 to 15 percent market share target within three years, and Poland, positioned for a meaningful presence by late 2027. Australia, Brazil, and smaller European markets are under evaluation. - What protects against price compression?
Three brands: Avai in premium, Zoic in value, and Viamede for the clinical patient.
Source: IgniteIt: Organigram Wants More Than Revenue From Germany. It Wants the Whole Margin.